61 assets in Uveal Melanoma

Therapeutic assets addressing Uveal Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Uveal Melanoma	Beijing Biotech	P2/3	BB (70)
Sargramostim Uveal Melanoma	Thomas Jefferson University	P3	BB (70)
Darovasertib Uveal Melanoma	IDEAYA Biosciences	P3	BB (69)
Pembrolizumab Uveal Melanoma	BioInvent International AB	P2/3	BB (68)
Melphalan Uveal Melanoma	Vastra Gotaland Region	P3	BB (67)
Dacarbazine Uveal Melanoma	IDEAYA Biosciences	P3	BB (66)
Tebentafusp Uveal Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P3	BB (66)
Nivolumab Uveal Melanoma	Inge Marie Svane	P3	BB (65)
Crizotinib Uveal Melanoma	IDEAYA Biosciences	P2/3	BB (64)
Ipilimumab Uveal Melanoma	Inge Marie Svane	P3	BB (64)
Cis-Diamminedichloroplatinum Ii Uveal Melanoma	iOnctura	P2	B (60)
Fludarabine Uveal Melanoma	Beijing Biotech	P2	B (60)
Camustine Uveal Melanoma	Thomas Jefferson University	P2	B (58)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Uveal Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P2	B (58)
Roginolisib Uveal Melanoma	St Vincent's Hospital, Sydney	P2	B (58)
Trametinib Uveal Melanoma	Alliance for Clinical Trials in Oncology	P2	B (58)
Bel-Sar Uveal Melanoma	Aura Biosciences	P3	B (57)
Binimetinib Uveal Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P2	B (57)
Melatonin Uveal Melanoma	Gustav Stalhammar	P3	B (57)
Tislelizumab Uveal Melanoma	Grupo Español Multidisciplinar de Melanoma	P2	B (57)
Vorinostat Uveal Melanoma	University of Miami	P2	B (57)
Ziv-Aflibercept Uveal Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P2	B (57)
rp2 Uveal Melanoma	Replimune, Inc.	P2/3	CCC (54)
Belinostat Uveal Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P2	CCC (53)
Iodized Ethyl Esters Of Poppyseed Fatty Acids Uveal Melanoma	Thomas Jefferson University	P2	CCC (53)
Lenvatinib Uveal Melanoma	Providence Health & Services	P2	CCC (53)
Olaparib Uveal Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P2	CCC (53)
Quisinostat Uveal Melanoma	University of Miami	P2	CCC (53)
TIL Uveal Melanoma	Udai Kammula	P2	CCC (53)
Uprosertib Uveal Melanoma	National Cancer Institute (NCI)	P2	CCC (53)
Valproic Acid Uveal Melanoma	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	P2	CCC (52)
Sitravatinib Uveal Melanoma	Grupo Español Multidisciplinar de Melanoma	P2	CCC (51)
Adoptive Therapy With Autologous Mc2 Tcr T Cells Uveal Melanoma	Erasmus Medical Center	P1/2	CCC (48)
Alocelyvir Uveal Melanoma	José María Piulats Rodríguez	P1/2	CCC (48)
bi-1607 Uveal Melanoma	BioInvent International AB	P1/2	CCC (48)
Spartalizumab Uveal Melanoma	SOLTI Breast Cancer Research Group	P2	CC (46)
Apg 115 Uveal Melanoma	Ascentage Pharma Group Inc.	P1/2	CC (45)
dyp688 Uveal Melanoma	Novartis Pharmaceuticals	P1/2	CC (45)
Eb-Dtkn-401 Allogeneic Dual-Target Cspg4/Gd2 Car-Nk Cells Uveal Melanoma	Beijing Biotech	P1/2	CC (45)
Nbm-Bmx Uveal Melanoma	Novelwise Pharmaceutical Corporation	P1/2	CC (45)
plx2853 Uveal Melanoma	Alliance for Clinical Trials in Oncology	P1/2	CC (45)
Vmd-102 Uveal Melanoma	VM Discovery, Inc.	P1/2	CC (45)
Lifileucel Uveal Melanoma	Vastra Gotaland Region	P1	CC (44)
Tbio-4101 Uveal Melanoma	Turnstone Biologics, Corp.	P1	CC (44)
[225ac]ac-a9-3408 Uveal Melanoma	Alpha-9 Oncology USA Inc.	P1	CC (43)
mbs8 Uveal Melanoma	MonTa Biosciences ApS	P1	CC (43)
225Ac-MTI-201 Uveal Melanoma	Modulation Therapeutics, Inc.	P1	CC (41)
4.7 microci 225ac-mti-201 Uveal Melanoma	Modulation Therapeutics, Inc.	P1	CC (41)
998 microci of 225ac-mti-201 Uveal Melanoma	Modulation Therapeutics, Inc.	P1	CC (41)
Autologous Anti-Cd19 Car-Expressing T Lymphocytes Uveal Melanoma	Anusha Kalbasi	P1	CC (41)

Showing 1 to 50 of 61 assets

PreviousPage 1 of 2Next